Hepatitis C (HCV)
- An interferon-free therapy for chronic HCV-1 & HIV co-infected individuals (C-ASCENT)
- Whether a daily dose of a statin medication (i.e. pitavastatin) lowers the risk of heart-related disease among people living with HIV (REPRIEVE).
- A specialized HIV test that can detect HIV as early as one week after exposure to the virus (The Early Test).
- One strategy on the pathway to possibly curing HIV by activating hidden HIV in the body so that it comes out to places where HIV medications can work to destroy it (Kick and Kill).
- Whether adding maraviroc and/or dolutegravir to a stable ARV regimen will improve one's ability to concentrate, remember, solve problems and make decisions (HAND).
- The effects of ruxolitinib on inflammation in HIV.
- The safety and efficacy of MK-1439A in ARV-naive subjects with HIV-1 and selected NNRTI-transmitted resistance mutations.
- Perturbing the HIV reservoir with immune stimulation, using the flu and pneumonia vaccines (Perturb).
- What happens and the safety of when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals (A5345; starting in May/June 2017).
- The safety, tolerability, pharmacokinetics and antiviral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy (starting in May/June 2017).
Pre-Exposure Prophylaxis (PrEP)
- HIV prevention methods with HIV-negative cisgender women using pre-exposure prophylaxis (PrEP) and text messaging (AEGiS).
- A novel wireless ingestible sensor system for measurement of medication adherence in HIV prevention for men and women.
- The safety and efficacy of Descovy (F/TAF) for PrEP in men and transgender women who have sex with men and are at risk of HIV-1 infection (DISCOVER).
- HIV prevention methods with HIV-negative transgender and gender non-conforming persons using pre-exposure prophylaxis (PrEP) and text messaging (starting in May 2017).
Women's Reproductive Health (for HIV-negative individuals)
- An investigational drug called Lactin-V that may prevent recurrent bacterial vaginosis or BV (LACTIN-V).
To learn more about these and other current clinical trials, please call us at (619) 543-8080 and ask for the Screening Coordinator.
Page 'Breadcrumb' Navigation: